Trials / Completed
CompletedNCT00930098
A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 74 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
This study is for a population of patients with few or no alternative options that was conducted to determine the response rate to clofarabine. Additionally the study will provide information on the safety profile, impact of overall survival, and impact on remission duration with clofarabine. It is a single arm study and has no comparator.
Detailed description
Note: This clinical trial was conducted by Bioenvision Ltd. Bioenvision Ltd. was acquired by Genzyme Corporation Oct 2007.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clofarabine |
Timeline
- Start date
- 2003-12-01
- Completion
- 2007-07-01
- First posted
- 2009-06-30
- Last updated
- 2014-02-11
Locations
36 sites across 6 countries: Austria, France, Germany, Italy, Netherlands, United Kingdom
Source: ClinicalTrials.gov record NCT00930098. Inclusion in this directory is not an endorsement.